Skip to main content

Advertisement

Table 4 Adverse events as reason for study termination reported in at least 1 patient in the total group (sorted by percentages in the total group).

From: Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?

Age 6-12 years N = 583 13-18 years N = 239 All patients N = 822
Adverse event (AE) [preferred term] n % n % n %
Patients with at least one AE* 48 8.23 12 5.02 60 7.30
Insomnia 16 2.74 3 1.26 19 2.31
Anorexia 6 1.03 2 0.84 8 0.97
Emotional lability 4 0.69 3 1.26 7 0.85
Muscle contractions involuntary 6 1.03 1 0.42 7 0.85
Depression 3 0.51 3 1.26 6 0.73
Abdominal pain 5 0.86 0 0.00 5 0.61
Aggressive reaction 4 0.69 1 0.42 5 0.61
Nervousness 4 0.69 1 0.42 5 0.61
Headache 1 0.17 3 1.26 4 0.49
Nausea 3 0.51 1 0.42 4 0.49
Apathy 1 0.17 2 0.84 3 0.36
Tachycardia 2 0.34 1 0.42 3 0.36
Anxiety 2 0.34 0 0.00 2 0.24
Concentration impaired 1 0.17 1 0.42 2 0.24
Dysphagia 2 0.34 0 0.00 2 0.24
Weight decrease 1 0.17 1 0.42 2 0.24
  1. * Chi2- Test: p = 0.144; some patients had more than one AE.